Consumers need products tailored to health or personal circumstances
The Exeter research findings
IP applications grow 7% in 2025
CI ‘survival period' reduced for new policyholders
£38m paid out for prostate cancer in 2025
Faster evidence. Clearer updates. Better support. Changes that could ease the bottleneck.